To establish and validate human planar neural organoids (PNOs) seeded with pediatric diffuse midline glioma (DMG) patient-derived xenograft (PDX) cell lines for preclinical drug testing, addressing the limitations of traditional models.
Key Findings:
DMG cell lines spatially integrate into human neural PNOs.
Tumor-seeded PNOs recapitulate known genetic signatures from patient samples.
PNOs demonstrate similar transcriptomic and proteomic landscapes to patient tumors.
The PNO system is superior for off-target toxicity screening compared to traditional monoculture.
Interpretation:
The study provides a proof of concept for using human-derived PNOs as a more accurate model for studying DMG and for preclinical drug testing, effectively addressing the limitations of traditional models.
Limitations:
The study primarily focuses on pediatric DMG and may not be generalizable to other tumor types, such as adult gliomas.
Further validation is needed to assess the long-term stability and reproducibility of PNOs.
Conclusion:
Human neural organoids represent a promising platform for modeling complex tumor microenvironments and enhancing preclinical drug testing.
by Jack M. Shireman, Elliot Xie, Connie S. Lebakken, Sudarshawn Damodharan, Kailyn T. Parham, William D. Richards, Rintaro Hashizume, Christina Kendziorski, Mahua Dey
